One Dieter's Story
Lisa Sutter, who lives in suburban Washington D.C., credits Belviq with helping her lose 40 pounds.
At the FDA hearing in May, Sutter told the panel that she gained weight after her children were born and found it impossible to lose it before enrolling in the trial.
"When I was on the drug I was able to stick to a 1,500- or 1,600-calorie-a-day diet without feeling hungry," she told WebMD. "And when I ate more than I planned to, I felt uncomfortably full, which is not something that I was used to."
Sutter was switched to the placebo arm of the study in her second year of enrollment and the weight started to creep back on.
She now weighs 30 pounds more than she did before enrolling in the trial and she says she plans to go back on the drug as soon as she can.
"I'm not saying this drug is the answer for everyone, but it worked well for me," she says.
Belviq Appears Safe, but Concerns Remain
But an FDA panel that met to consider the drug in 2010 had other concerns about the drug's safety, citing tumors that developed in lab animals.
At the FDA hearing in May, some panel members continued to express concerns that the drug may cause breast tumors or heart valve problems.
The panel voted 18 to 4 to recommend the drug's approval, citing the need for new obesity treatments.
"Obesity is one of the biggest health problems we face in this nation and, unfortunately the diet and lifestyle message is not working for many people," says diabetes specialist Abraham Thomas, MD, who chaired the May FDA advisory committee meeting.
Thomas, who is an endocrinologist at Henry Ford Hospital in Detroit, said during the May meeting that questions about heart valve safety in Belviq users had not been fully resolved.
But in an interview with WebMD, he called echocardiogram findings in Belviq users reassuring. These tests showed no evidence of an increase in heart valve issues.